The electronic cigarettes segment by product is estimated to lead the market growth during the forecast period.
According to a new market research study of “South and Central America Smoking Cessation Aids Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Product, End-user and Country.” The South and Central America smoking cessation aids market is expected to reach US$ 2,394.81 million in 2028 from US$ 1,004.42 million in 2021; it is estimated to grow at a CAGR of 13.2% from 2021 to 2028. The report highlights trends prevailing in the South and Central America smoking cessation aids market and the factors driving market along with those that act as hindrances. Key factors that are driving the growth of this market are rising addiction toward tobacco smoking and increasing number of campaigns to reduce smoking and tobacco dependence. However, steeping costs for development of nicotine replacement therapies are likely to restrain the market growth in the future years to some extent.
The smoking of tobacco is proven to be dangerous in all forms as it can lead to chronic health conditions, preventable diseases, deaths, and disabilities. According to the World Health Organization (WHO), smoking-related disorders result in about 435,000 deaths per year in the US, which equals to around 1 in 5 of the total deaths in the country. Therefore, prevalence of tobacco smoking is high across various countries in the North America that drives the growth of the smoking cessation aids market. The government and nongovernment organizations worldwide are coming forward and launching campaigns to provide awareness and undertake measures to curb the diseases caused due to smoking and tobacco consumption. The measures are taken to reduce the economic and health burden caused due to cigarette smoking in countries worldwide. For instance, every year on May 31st, the WHO along with its global partners celebrate World No Tobacco Day (WNTD) to spread education and awareness regarding the harmful and deadly effects of tobacco and second-hand smoke exposure. Initiatives undertaken on this day mainly aim to discourage the consumption of tobacco in any form and educate people regarding the availability of aids that assist in smoking cessation. The launch of anti-smoking campaigns is organized on global, national, and regional levels worldwide. The governments of various countries have increased excise duties and taxes on tobacco-based cigarettes and cigars to reduce its affordability, thus consumption among common populace. In addition, numerous governments have legalized the use of e-cigarettes as a smoking cessation aid under licensed sales channels to prevent people from opting conventional cigarettes. Thus, the increasing efforts undertaken by governments as well as non-profit and nongovernment organizations to promote the use of smoking cessation aids and reduce the number of smoking populations boost the growth of the market.
The South and Central America region is highly affected due to the outbreak of the COVID-19 pandemic. Over the past two decades, Brazil has been at the forefront of global tobacco control initiatives. Brazil has thrown its weight behind nicotine replacement therapies - a move strongly endorsed by the World Health Organization (WHO), which has put nicotine replacement therapy on the Essential Medicines List (EML). Such government initiatives are helping the market to grow. Moreover, during this COVID-19 situation, researchers are evaluating the results for the nicotine usage in preventing COVID-19 pandemic. It states that there is insufficient information to confirm link between tobacco or nicotine in the treatment of COVID-19. Hence, COVID-19 pandemic does not show significant impact on smoking cessation aids market.
The South and Central America smoking cessation aids market, by product, is segmented into nicotine replacement therapy, drugs, electronic cigarettes, and others. Based on End-user, the South and Central America smoking cessation aids market is segmented into hospital pharmacies, online channel, retail pharmacies, and other End-users. Geographically, the South and Central America smoking cessation aids market can be bifurcated into Brazil, Argentina and Rest of South and Central America.
Pfizer Inc. GlaxoSmithKline plc. Dr. Reddy's Laboratories, Johnson and Johnson Services, Inc. Cipla Inc. Perrigo Company plc, Bausch Health Companies Inc. and Glenmark are among the leading companies operating in the South and Central America smoking cessation aids market
According to a new market research study of “South and Central America Smoking Cessation Aids Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Product, End-user and Country.” The South and Central America smoking cessation aids market is expected to reach US$ 2,394.81 million in 2028 from US$ 1,004.42 million in 2021; it is estimated to grow at a CAGR of 13.2% from 2021 to 2028. The report highlights trends prevailing in the South and Central America smoking cessation aids market and the factors driving market along with those that act as hindrances. Key factors that are driving the growth of this market are rising addiction toward tobacco smoking and increasing number of campaigns to reduce smoking and tobacco dependence. However, steeping costs for development of nicotine replacement therapies are likely to restrain the market growth in the future years to some extent.
The smoking of tobacco is proven to be dangerous in all forms as it can lead to chronic health conditions, preventable diseases, deaths, and disabilities. According to the World Health Organization (WHO), smoking-related disorders result in about 435,000 deaths per year in the US, which equals to around 1 in 5 of the total deaths in the country. Therefore, prevalence of tobacco smoking is high across various countries in the North America that drives the growth of the smoking cessation aids market. The government and nongovernment organizations worldwide are coming forward and launching campaigns to provide awareness and undertake measures to curb the diseases caused due to smoking and tobacco consumption. The measures are taken to reduce the economic and health burden caused due to cigarette smoking in countries worldwide. For instance, every year on May 31st, the WHO along with its global partners celebrate World No Tobacco Day (WNTD) to spread education and awareness regarding the harmful and deadly effects of tobacco and second-hand smoke exposure. Initiatives undertaken on this day mainly aim to discourage the consumption of tobacco in any form and educate people regarding the availability of aids that assist in smoking cessation. The launch of anti-smoking campaigns is organized on global, national, and regional levels worldwide. The governments of various countries have increased excise duties and taxes on tobacco-based cigarettes and cigars to reduce its affordability, thus consumption among common populace. In addition, numerous governments have legalized the use of e-cigarettes as a smoking cessation aid under licensed sales channels to prevent people from opting conventional cigarettes. Thus, the increasing efforts undertaken by governments as well as non-profit and nongovernment organizations to promote the use of smoking cessation aids and reduce the number of smoking populations boost the growth of the market.
The South and Central America region is highly affected due to the outbreak of the COVID-19 pandemic. Over the past two decades, Brazil has been at the forefront of global tobacco control initiatives. Brazil has thrown its weight behind nicotine replacement therapies - a move strongly endorsed by the World Health Organization (WHO), which has put nicotine replacement therapy on the Essential Medicines List (EML). Such government initiatives are helping the market to grow. Moreover, during this COVID-19 situation, researchers are evaluating the results for the nicotine usage in preventing COVID-19 pandemic. It states that there is insufficient information to confirm link between tobacco or nicotine in the treatment of COVID-19. Hence, COVID-19 pandemic does not show significant impact on smoking cessation aids market.
The South and Central America smoking cessation aids market, by product, is segmented into nicotine replacement therapy, drugs, electronic cigarettes, and others. Based on End-user, the South and Central America smoking cessation aids market is segmented into hospital pharmacies, online channel, retail pharmacies, and other End-users. Geographically, the South and Central America smoking cessation aids market can be bifurcated into Brazil, Argentina and Rest of South and Central America.
Pfizer Inc. GlaxoSmithKline plc. Dr. Reddy's Laboratories, Johnson and Johnson Services, Inc. Cipla Inc. Perrigo Company plc, Bausch Health Companies Inc. and Glenmark are among the leading companies operating in the South and Central America smoking cessation aids market
Reasons to buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the South and Central America smoking cessation aids market
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the South and Central America smoking cessation aids market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction
3. Research Methodology
4. South and Central America Smoking Cessation Aids Market - Market Landscape
5. Smoking Cessation Aids Market - Key Market Dynamics
6. Smoking Cessation Aids Market -South and Central America Analysis
7. Smoking Cessation Aids Market Analysis - By Product
8. Smoking Cessation Aids Market Analysis - By End User
9. Smoking Cessation Aids Market - South and Central America Analysis
10. Impact of COVID-19 Pandemic on South and Central America Smoking Cessation Aids Market
11. Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc.
- GlaxoSmithKline plc.
- Dr. Reddy's Laboratories
- Johnson and Johnson Services, Inc.
- Cipla Inc.
- Perrigo Company plc
- Bausch Health Companies Inc.
- Glenmark
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 114 |
Published | August 2021 |
Forecast Period | 2021 - 2028 |
Estimated Market Value ( USD | $ 1004.42 Million |
Forecasted Market Value ( USD | $ 2394.81 Million |
Compound Annual Growth Rate | 13.2% |